Regulatory intelligence software promises to keep your team ahead of changing agency expectations. In practice, most of it delivers the same thing: a searchable firehose of guidances, notices, and news, plus email alerts that everyone filters into a folder and reads never. The 2026 evaluation question has shifted. It is no longer ‘does this tool cover the sources?’ — public agency data has never been more accessible — but ‘does this tool know my portfolio well enough to tell me what matters?’ That difference, generic feed versus portfolio-aware scoring, is the dividing line in the category.

The Firehose Problem

A mid-size company with a dozen active applications faces a steady stream of potentially relevant events: new and revised FDA guidances, Federal Register notices, EMA committee outcomes, MHRA updates, approval precedents in their therapeutic areas, recalls and enforcement actions touching their drug classes. Traditional intelligence platforms — the Cortellis-style databases — index all of it comprehensively. Comprehensiveness is their value and their failure mode: every item arrives with equal weight, so a busy RA team either assigns someone to triage the feed manually (expensive, inconsistent) or stops reading it (common, unspoken).

What Portfolio-Aware Intelligence Looks Like

The alternative approach inverts the model. Instead of asking the user to filter the world’s regulatory news, the software holds a structured picture of the user’s portfolio — applications, agencies, submission types, therapeutic context, active programs — and scores every incoming item against it. The output isn’t ‘FDA published 14 things this week’; it’s ‘this draft guidance on nitrosamine limits is rated high-impact for two of your applications, here’s why, and the comment deadline is in 45 days.’

Concretely, a portfolio-aware system should provide:

  • Impact scoring per item, per application. An AI assessment of each news item or guidance against your actual filings — not a generic therapeutic-area tag.
  • A triage workflow, not just alerts. Items classified as Inform-Only versus Potential-Impact, with Potential-Impact items routed to a named SME for assessment and, where warranted, escalated into change control. Intelligence that can’t become an assigned action is trivia.
  • A guidance and consultation tracker. A structured register of the guidances you’re following — impact ratings, affected products, comment deadlines, internal owners — replacing the inevitable ‘Guidance Tracker.xlsx’.
  • Approval precedent data. Recent approvals in your space with computed review timelines, because ‘how long did similar applications take?’ is a planning input, not a curiosity.
  • Digest output. A periodic, readable intelligence summary generated from the scored feed — the artifact RA leadership actually forwards.

The Sources Are Free. The Judgment Isn’t.

An underappreciated fact of 2026: the primary sources are largely free and machine-readable. The US Federal Register has a clean public API. openFDA publishes approvals, recalls, and enforcement actions. EMA and MHRA publish structured feeds. A modern platform can ingest all of these live without a licensing fee — which means you should be skeptical of intelligence products whose main claim is access to public data. What you are actually buying in this category is the judgment layer: portfolio matching, impact scoring, deadline extraction, and workflow. Evaluate that layer, not the source list.

How DnXT Approaches Regulatory Intelligence

DnXT Planner includes a regulatory intelligence suite built on exactly this philosophy. Live ingestion covers the Federal Register, openFDA approvals and enforcement data, EMA and MHRA feeds, plus a generic ingester for any public RSS source your team follows. Every item is scored by AI against the applications in your portfolio — the same application records your submissions and correspondence already live in — and lands on a triage board as Inform-Only or Potential-Impact, with SME routing for the latter. A 14-column guidance and consultation tracker replaces the spreadsheet, a PDUFA and approval-precedent view computes median review times from live data, and AI-generated digest newsletters summarize the week’s scored items. Because impact scoring runs against your portfolio inside the same platform, there’s no export-import loop between your intelligence tool and your planning tool — a separation that quietly kills most intelligence programs.

Frequently Asked Questions

What is regulatory intelligence software?

Software that monitors regulatory-agency activity — guidances, notices, approvals, enforcement — and turns it into assessed, actionable information for regulatory affairs teams. Mature tools add impact assessment, ownership, and workflow on top of monitoring.

How is portfolio-aware scoring different from keyword alerts?

Keyword alerts match text; portfolio-aware scoring matches meaning against your filings. A keyword alert on your drug class fires on every mention. A portfolio-aware score reads the item, compares it to each of your applications’ context, and rates the impact with a rationale — so triage starts from a ranked list instead of a raw feed.

Do we still need a commercial intelligence database?

For deep historical research and competitive intelligence across the whole industry, comprehensive databases retain real value. For operational surveillance of what affects your portfolio this quarter, live public sources plus a good judgment layer cover most of the need at a fraction of the cost.

Where should intelligence live organizationally?

Closest to planning. The output of intelligence is a change to a plan — a new section, a revised timeline, a comment submission. Tools and teams that keep intelligence and planning connected convert more surveillance into action.

If your intelligence process is a shared inbox and a spreadsheet, book a walkthrough — we’ll score a week of live agency output against a sample portfolio and show you what the triage board looks like with your kind of pipeline.